InnoCare Pharma Limited (9969.HK)
Develops cancer and autoimmune disease drugs for patients in China
13.97-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago-20.5%
The outlook
InnoCare Pharma trades at 13.97, sitting well above its short-term moving averages and roughly midway through its 52-week range. Analyst consensus is strongly bullish with an average price target about 43% above the current level. The stock carries a trailing P/E of 31.8, reflecting growth expectations priced into the valuation.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 8 analysts
Price trendAbove its 50- & 200-day averages
52-week range39% of the way from its 52-week low to high
Price targetAvg target +43% vs current price
Analyst price target
~12-month · 8 analysts19.93average target+42.6% vs now
Now 13.97
Low 17.03High 22.37
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$24.68B
52-wk high
20.62
52-wk low
9.65
50-day avg
12.23
200-day avg
13.11
Trailing P/E
31.8